Clinical and Translational Oncology

, Volume 12, Issue 2, pp 81–91

Chemotherapy-induced peripheral neuropathy: clinical features, diagnosis, prevention and treatment strategies

  • Gerardo Gutiérrez-Gutiérrez
  • María Sereno
  • Ambrosio Miralles
  • Enrique Casado-Sáenz
  • Eduardo Gutiérrez-Rivas
Educational Series Molecular Targets in Oncology


Chemotherapy-induced peripheral neuropathy (CIN) is a common toxicity of anticancer treatment and its incidence is growing. It significantly affects quality of life and is a dose-limiting factor that interferes with treatment. Its diagnosis can be established in clinical terms but some complementary tests can help when the diagnosis is difficult. There is still no proven method to prevent it that has become a standard of care in spite of the huge amount of investigation carried out in recent years. There are promising strategies that could help reduce the burden of this complication. This review will suggest an approach to the diagnosis of these disorders and provide an update on new therapies.


Chemotherapy Neuropathy Pain Cancer Polyneuropathy Neuroprotection 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Walker M, Ni O (2007) Neuroprotection during chemotherapy: a systematic review. Am J Clin Oncol 30:82–92CrossRefPubMedGoogle Scholar
  2. 2.
    Cavaletti G, Bogliun G, Marzorati L et al (1994) Long-term peripheral neurotoxicity of cisplatin in patients with successfully treated epithelial ovarian cancer. Anticancer Res 14:1287–1292PubMedGoogle Scholar
  3. 3.
    Mileshkin L, Antil Y, Rischin D (2002) Management of complications of chemotherapy. In: Gershenson DM, McGuire MP, Gore M et al (eds) Gynaecologic cancer: controversies in management. Elsevier Science, Philadelphia, PAGoogle Scholar
  4. 4.
    Wolf S, Barton D, Kottschade L et al (2008) Chemotherapy-induced neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507–1515CrossRefPubMedGoogle Scholar
  5. 5.
    Mileshkin L, Stark R, Day B et al (2006) Development of neuropathy in patients with myeloma treated with thalidomide: patterns of occurrence and the role of electrophysiologic monitoring. J Clin Oncol 24:4507–4514CrossRefPubMedGoogle Scholar
  6. 6.
    National Cancer Institute (NCI) (2006) Nerve changes in patients who are undergoing chemotherapy or biological therapy for cancer. In: [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: Google Scholar
  7. 7.
    MD Anderson Cancer (2009) Chemotherapy-induced peripheral neuropathy survey. In: ClinicalTrials. gov [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: Google Scholar
  8. 8.
    Gardner ED, Bunge RP (2005) Gross anatomy of the peripheral nervous system. In: Dyck PJ, Thomas PK (eds) Peripheral neuropathy, 4th edn. Elsevier, Philadelphia, pp 11–34Google Scholar
  9. 9.
    Berthold SH, Fraher JP, King RHM et al (2005) Microscopic anatomy of the peripheral nervous system. In: Dyck PJ, Thomas PK (eds) Peripheral neuropathy, 4th edn. Elsevier, Philadelphia, pp 35–91Google Scholar
  10. 10.
    Cecilia Conde C, Cáceres A (2009) Microtubule assembly, organization and dynamics in axons and dendrites. Nat Rev Neurosci 10:319–332CrossRefPubMedGoogle Scholar
  11. 11.
    Hughes R (2008) Peripheral nerve diseases. Pract Neurol 8:396–405CrossRefPubMedGoogle Scholar
  12. 12.
    Serra Catafau J (2006) Concepto de dolor neuropático. In: Serra Catafau J (ed.) Dolor neuropático. Médica Panamericana, Madrid, pp 17–26Google Scholar
  13. 13.
    Devigili G, Tugnoli V, Penza P et al (2008) The diagnostic criteria for small fibre neuropathy: from symptoms to neuropathology. Brain 131:1912–1925CrossRefPubMedGoogle Scholar
  14. 14.
    Hughes R (2008) Peripheral nerve diseases. Pract Neurol 8:396–405CrossRefPubMedGoogle Scholar
  15. 15.
    Pestronk A, Florence J, Levine T et al (2004) Sensory exam with a quantitative tuning fork. Rapid, sensitive and predictive of SNAP amplitude. Neurology 62:461–464PubMedGoogle Scholar
  16. 16.
    Martina IS, van Koningsveld R, Schmitz PI et al (1998) For the European Inflammatory Neuropathy Cause and Treatment (INCAT) group. Measuring vibration threshold with a graduated tuning fork in normal aging and in patients with polyneuropathy. J Neurol Neurosurg Psychiatry 65:743–747CrossRefPubMedGoogle Scholar
  17. 17.
    Botez SA, Liu G, Logigian E et al (2009) Is the bedside timed vibration test reliable? Muscle Nerve 39:221–223CrossRefPubMedGoogle Scholar
  18. 18.
    Zara G, Ermani M, Rondinone R et al (2008) Thalidomide and sensory neurotoxicity: a neurophysiological study. J Neurol Neurosurg Psychiatry 79:1258–1261CrossRefPubMedGoogle Scholar
  19. 19.
    Postma TJ, Heimans JJ (2000) Grading of chemotherapy- induced peripheral neuropathy. Ann Oncol 11:509–513CrossRefPubMedGoogle Scholar
  20. 20.
    Cascinu S, Catalano V, Cordella L et al (2002) Neuroprotective effect of reduced glutathione on oxaliplatin-based chemotherapy in advance colorectal cancer: a randomized, double-blind, placebo-controlled trial. J Clin Oncol 20:3478–3483CrossRefPubMedGoogle Scholar
  21. 21.
    Park SB, Lin CS-Y, Krishnan AV et al (2009) Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy. Brain 132:2712–2723CrossRefPubMedGoogle Scholar
  22. 22.
    Mileshkin L, Stark R, Day B et al (2006) Aparición de neuropatía en los pacientes con mieloma tratados con talidomida: patrones de aparición y utilidad de la monitorización electrofisiológica. J Clin Oncol 24:4507–4514CrossRefPubMedGoogle Scholar
  23. 23.
    American Association of Electrodiagnostic Medicine (2004) Technology literature review: quantitative sensory testing. Muscle Nerve 29:734–747CrossRefGoogle Scholar
  24. 24.
    Park SB, Goldstein D, Lin CS-Y et al (2009) Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity. J Clin Oncol 27:1243–1249CrossRefPubMedGoogle Scholar
  25. 25.
    Park SB, Krishnan AV, Lin CS-Y et al (2008) Mechanisms underlying chemotherapy-induced neurotoxicity and the potential for neuroprotective strategies. Curr Med Chem 15:3081–3094CrossRefPubMedGoogle Scholar
  26. 26.
    England JD, Gronseth GS, Franklin G et al (2009) Evaluation of distal symmetric polyneuropathy: the role of autonomic testing, nerve biopsy, and skin biopsy (an evidence-based review). Muscle Nerve 39:106–115CrossRefPubMedGoogle Scholar
  27. 27.
    Sommer C (2008) Skin biopsy as a diagnostic tool. Curr Opin Neurol 21:563–568CrossRefPubMedGoogle Scholar
  28. 28.
    Lauria G, Devigili G (2007) Skin biopsy as a diagnostic tool in peripheral neuropathy. Nat Clin Pract Neurol 3:546–557CrossRefPubMedGoogle Scholar
  29. 29.
    Lauria G, Lombardi R (2007) Skin biopsy: a new tool for diagnosing peripheral neuropathy. BMJ 334:1159–1162CrossRefPubMedGoogle Scholar
  30. 30.
    Erasmus Medical Center (2010) Skin biopsies in chemotherapy-induced neuropathy. In: [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: Google Scholar
  31. 31.
    Ruzzo A, Graziano F, Loupakis F et al (2007) Perfil farmacogenético en los pacientes con cancer colorrectalavanzado tratados con quimioterapia FOLFOX-4 de primera línea. J Clin Oncol 25:1247–1254CrossRefPubMedGoogle Scholar
  32. 32.
    Samsung Medical Center (2009) Pharmacogenomic study to predict neurotoxicity of oxaliplatin. In: [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091220. Available from: http://clinicaltrials. gov/ct2/show/NCT00977717?term=neuropathy+and+chemotherapy&rank=32 Google Scholar
  33. 33.
    Wolf S, Barton D, Kottschade L et al (2008) Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies. Eur J Cancer 44:1507–1515CrossRefPubMedGoogle Scholar
  34. 34.
    Lee JJ, Swain SM (2006) Peripheral neuropathy induced by microtubule-stabilizing agents. J Clin Oncol 24:1633–1642CrossRefPubMedGoogle Scholar
  35. 35.
    Camps C, Felip E, Sanchez JM et al (2005) Phase II trial of the novel taxane BMS-184476 as second-line in non-small-cell lung cancer. Ann Oncol 16:597–601CrossRefPubMedGoogle Scholar
  36. 36.
    Whitehead RP, McCoy S, Rivkin SE et al (2006) A Phase II trial of epothilone B analogue BMS-247550 (NSC #710428) ixabepilone, in patients with advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 24:515–520CrossRefPubMedGoogle Scholar
  37. 37.
    McKeage MJ, Hsu T, Screnci D et al (2001) Nucleolar damage correlates with neurotoxicity induced by different platinum drugs. Br J Cancer 85:1219–1225CrossRefPubMedGoogle Scholar
  38. 38.
    Ta LE, Low PA, Windebank AJ (2009) Mice with cisplatin and oxaliplatin-induced painful neuropathy develop distinct early responses to thermal stimuli. Mol Pain 26:5–9Google Scholar
  39. 39.
    Gill JS, Windebank AJ (1998) Cisplatin-induced apoptosis in rat dorsal root ganglion neurons is associated with attempted entry into the cell cycle. J Clin Invest 101:2842–2850CrossRefPubMedGoogle Scholar
  40. 40.
    Cubillo S, Cabello A, Trueba JL et al (1980) Cisplatinum neuropathy. Neurosci Lett 4[Suppl]:447Google Scholar
  41. 41.
    McKeage K (2007) Treatment options for the management of diabetic painful neuropathy: best current evidence. Curr Opin Neurol 20:553–557CrossRefPubMedGoogle Scholar
  42. 42.
    Hansen MB (2003) The enteric nervous system III: a target for pharmacological treatment. Pharmacol Toxicol 93:1–13CrossRefPubMedGoogle Scholar
  43. 43.
    Krishnan AV, Kiernan MC (2006) Axonal function and activity-dependent excitability changes in myotonic dystrophy. Muscle Nerve 33:627–636CrossRefPubMedGoogle Scholar
  44. 44.
    McKeage MJ (1995) Comparative adverse effect profiles of platinum drugs. Drug Saf 13:228–244CrossRefPubMedGoogle Scholar
  45. 45.
    Gutiérrez-Rivas E, Alonso-Ortiz A, Téllez I et al (1984) Vindesine-induced neuropathy. Neurosci Lett 18[Suppl]:40Google Scholar
  46. 46.
    Pan YA, Misgeld T, Lichtman JW et al (2003) Effects of neurotoxic and neuroprotective agents on peripheral nerve regeneration assayed by time-lapse imaging in vivo. J Neurosci 23:11479–11488PubMedGoogle Scholar
  47. 47.
    Kalcioglu MT, Kuku I, Kaya E et al (2003) Bilateral hearing loss during vincristine therapy: a case report. J Chemother 15:290–292PubMedGoogle Scholar
  48. 48.
    Verstappen CC, Koeppen S, Heimans JJ et al (2005) Dose-related vincristine-induced peripheral neuropathy with unexpected off-therapy worsening. Neurology 64:1076–1077PubMedGoogle Scholar
  49. 49.
    Ramchandren S, Leonard M, Mody RJ et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukemia. J Peripher Nerv Syst 14:184–189CrossRefPubMedGoogle Scholar
  50. 50.
    Cavaletti G, Nobile-Orazio E (2007) Bortezomib-induced peripheral neurotoxicity: still far from a painless gain. Haematologica 92:1308–1310CrossRefPubMedGoogle Scholar
  51. 51.
    Moehler TM, Hillengass J, Glasmacher A et al (2006) Thalidomide in multiple myeloma. Curr Pharm Biotechnol 7:431–440CrossRefPubMedGoogle Scholar
  52. 52.
    Rabasa M, Gutiérrez-Rivas E, Díaz J et al (1994) Neuropatía tóxica por Talidomida. Neurología 9:477Google Scholar
  53. 53.
    Kotla V, Goel S, Nischal S et al (2009) Mechanism of action of lenalidomide in hematological malignancies. J Hematol Oncol 2:36CrossRefPubMedGoogle Scholar
  54. 54.
    Openshaw H, Slatkin NE, Stein AS et al (1996) Acute polyneuropathy after high dose cytosine arabinoside in patients with leukemia. Cancer 78:1899–1905CrossRefPubMedGoogle Scholar
  55. 55.
    Alonso-Ortiz A, Gutiérrez-Rivas E, Cabello A et al (1990) Toxic neuropathy induced by Ara-C. J Neurol Sci 98:265Google Scholar
  56. 56.
    Thant M, Hawley RJ, Smith MT et al (1982) Possible enhancement of vincristine neuropathy by VP-16. Cancer 1:859–864CrossRefGoogle Scholar
  57. 57.
    Dormann AJ, Grunewald T, Wigginghaus B et al (1998) Gemcitabine-associated autonomic neuropathy. Lancet 351:644CrossRefPubMedGoogle Scholar
  58. 58.
    Sherman JE, Aregawi MD, Lai A, Fathallah-Shaykh M (2009) Optic neuropathy in patients with glioblastoma receiving bevacizumab. Neurology 73:1924–1926CrossRefPubMedGoogle Scholar
  59. 59.
    Burnett AK, Kell J (2007) Tipifarnib in acute myeloid leukemia. Drugs Today (Barc) 43:795–800CrossRefGoogle Scholar
  60. 60.
    Kovacs MJ, Reece DE, Marcellus D et al (2006) A phase II study of ZD6474 (Zactima, a selective inhibitor of VEGFR and EGFR tyrosine kinase in patients with relapsed multiple myeloma: NCIC CTG IND.145. Invest New Drugs 24:529–535PubMedGoogle Scholar
  61. 61.
    Gutiérrez-Rivas E, Alonso-Ortiz A, Cabello A et al (1984) Toxic neuropathy due to prospidium. Neurosci Lett 18[Suppl]:403Google Scholar
  62. 62.
    Esteban PM, Thahn TG, Bravo JF et al (2009) Malnutrition associated with increased risk of peripheral neuropathy in Peruvian children with HIV infection. J Acquir Immune Defic Syndr 52:656–658PubMedGoogle Scholar
  63. 63.
    Gomber S, Dewan P, Chhonker D (2009) Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr (published online)Google Scholar
  64. 64.
    de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938–2947PubMedGoogle Scholar
  65. 65.
    de Gramont A, Cervantes A, Andre T et al (2004) OPTIMOX study: FOLFOX7/LV5FU2 compared to FOLFOX4 in patients with advanced colorectal cancer. J Clin Oncol 22:3525Google Scholar
  66. 66.
    Ghirardi O, Lo Giudice P, Pisano C et al (2005) Acetyl-L-carnitine prevents and reverts experimental chronic neurotoxicity induced by oxaliplatin, without altering its antitumor properties. Anticancer Res 25:2681–2687PubMedGoogle Scholar
  67. 67.
    Bianchi G, Vitali G, Caraceni A et al (2005) Symptomatic and neurophysiological responses of paclitaxel- or cisplatin-induced neuropathy to oral acetyl-L-carnitine. Eur J Cancer 41:1746–1750CrossRefPubMedGoogle Scholar
  68. 68.
    Daikhin Y, Yudkoff M (2000) Compartmentation of brain glutamate metabolism in neurons and glia. J Nutr 130:1026S–1031SPubMedGoogle Scholar
  69. 69.
    Gedlicka C, Kornek GV, Schmid K et al (2003) Amelioration of docetaxel/cisplatin induced polyneuropathy by alpha-lipoic acid. Ann Oncol 14:339–340CrossRefPubMedGoogle Scholar
  70. 70.
    Leonetti C, Biroccio A, Gabellini C et al (2003) Alpha-tocopherol protects against cisplatin-induced toxicity without interfering with antitumor efficacy. Int J Cancer 104:243–250CrossRefPubMedGoogle Scholar
  71. 71.
    Argyriou AA, Chroni E, Koutras A et al (2006) A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin-induced peripheral neuropathy: final results. Support Care Cancer 14:1134–1140CrossRefPubMedGoogle Scholar
  72. 72.
    Ferreira PR, Fleck JF, Diehl A et al (2004) Protective effect of alpha-tocopherol in head and neck cancer radiation-induced mucositis: a double-blind randomized trial. Head Neck 26:313–321CrossRefPubMedGoogle Scholar
  73. 73.
    MD Anderson Cancer Center (2005) Alpha-lipoic acid in preventing peripheral neuropathy in patients receiving chemotherapy for cancer. In: [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091219. Available from: Google Scholar
  74. 74.
    So YT, Simon RP (2007) Deficiency diseases of the nervous system. In: Bradley WG, Daroff RB, Fenichel GM et al (eds) Neurology in clinical practice, 5th edn. Butterworth-Heinemann, Philadelphia, pp 1643–1656Google Scholar
  75. 75.
    Ang CD, Alviar MJM, Dans AL et al (2008) Vitamina B para el tratamiento de la neuropatía periférica (Revisión Cochrane traducida). En: La Biblioteca Cochrane Plus, Número 4. Update Software Ltd., Oxford. Available from: (Traducida de The Cochrane Library, 2008 Issue 3. John Wiley & Sons, Ltd., Chichester, UK)Google Scholar
  76. 76.
    New Mexico Cancer Care Alliance (2008) A randomized phase III study of vitamins B6 and B12 to prevent chemotherapy-induced neuropathy in cancer patients. In: [Internet]. National Library of Medicine (US), Bethesda, MD. 2000-20091222. Available from: Google Scholar
  77. 77.
    Ramchandren S, Leonard M, Mody RJ et al (2009) Peripheral neuropathy in survivors of childhood acute lymphoblastic leukaemia. J Periph Nerv Syst 14:184–189CrossRefGoogle Scholar
  78. 78.
    Kore DH, Donnelly J, McGuire WP et al (2003) Limited access trial using amifostine for protection against cisplatin- and three-hour paclitaxel-induced neurotoxicity: a phase II study of the Gynecologic Oncology Group. J Clin Oncol 21:4207–4213CrossRefGoogle Scholar
  79. 79.
    Argyriou AA, Chroni E, Polychronopoulos P et al (2006) Efficacy of oxcarbazepine for prophylaxis against cumulative oxaliplatin-induced neuropathy. Neurology 67:2253–2255CrossRefPubMedGoogle Scholar
  80. 80.
    Gamelin L, Boisdron-Celle M, Delva R et al (2004) Prevention of oxaliplatin-related neurotoxicity by calcium and magnesium infusions: a retrospective study of 161 patients receiving oxaliplatin combined with 5-fluorouracil and leucovorin for advanced colorectal cancer. Clin Cancer Res 10:4055–4061CrossRefPubMedGoogle Scholar
  81. 81.
    Saif MW, Reardon J (2005) Management of oxaliplatin-induced peripheral neuropathy. Ther Clin Risk Manag 1:249–258PubMedGoogle Scholar
  82. 82.
    Hamers FP, Brakkee JH, Cavalletti E et al (1993) Reduced glutathione protects against cisplatin-induced neurotoxicity in rats. Cancer Res 53:544–549PubMedGoogle Scholar
  83. 83.
    Cassidy J, Bjarnason G, Hickish T et al (2006) Randomized double blind placebo controlled phase III study assessing the efficacy of xaliproden in reducing the cumulative peripheral sensory neuropathy induced by the oxaliplatin and 5FU/LV combination in first line treatment of patients with metastatic colorectal cancer. J Clin Oncol 24:3507. Abstr 229Google Scholar
  84. 84.
    Traa BS, Mulholland JD, Kadam SD et al (2008) Gabapentin neuroprotection and seizure suppression in immature mouse brain ischemia. Pediatr Res 64:81–85CrossRefPubMedGoogle Scholar
  85. 85.
    Cassidy J, Paul J, Soukop M et al (1998) Clinical trials of nimodipine as a potential neuroprotector in ovarian cancer patients treated with cisplatin. Cancer Chemother Pharamacol 41:161–166CrossRefGoogle Scholar
  86. 86.
    Hilton DJ (1992) LIF: lots of interesting functions. Trends Biochem Sci 17:72–76CrossRefPubMedGoogle Scholar
  87. 87.
    Mamiya N, Kono T, Mamiya K et al (2007) A case of neurotoxicity reduced with goshajinkigan in modified FOLFOX6 chemotherapy for advanced colon cancer. Gan To Kagaku Ryoho 34:1295–1297PubMedGoogle Scholar
  88. 88.
    Shindo Y, Tenma K, Imano H et al (2008) Reduction of oxaliplatin-related neurotoxicity. Gan To Kagaku Ryoho 35:863–865PubMedGoogle Scholar
  89. 89.
    van der Hoop RG, Vetch GJ, van der Burg ME et al (1990) Prevention of cisplatin neurotoxicity with ovarian cancer. N Engl J Med 322:89–94PubMedCrossRefGoogle Scholar
  90. 90.
    Jackson JH (1932) Evolution and dissolution of the nervous system (Croonian Lecture). Selected writings of John Hughlings Jackson, vol. 2. Hodder and Stoughton, LondonGoogle Scholar

Copyright information

© Feseo 2010

Authors and Affiliations

  • Gerardo Gutiérrez-Gutiérrez
    • 1
  • María Sereno
    • 2
  • Ambrosio Miralles
    • 1
  • Enrique Casado-Sáenz
    • 2
  • Eduardo Gutiérrez-Rivas
    • 3
  1. 1.Neurology DepartmentInfanta Sofía HospitalSan Sebastián de los Reyes, MadridSpain
  2. 2.Medical Oncology DepartmentInfanta Sofía HospitalSan Sebastián de los Reyes, MadridSpain
  3. 3.Neuromuscular Unit Neurology DepartmentHospital Universitario 12 de OctubreMadridSpain

Personalised recommendations